← SynDRA
AVOSENTAN
SynDRA canonical compound SYN0039067 — structure-anchored drug synonym record
| Clinical phase | Phase 3 |
|---|
| Primary target(s) | EDNRA |
|---|
| Mechanism of action | endothelin receptor antagonist |
|---|
All known targets
Mechanisms of action (all sources)
- EDNRA ANTAGONIST
- Endothelin receptor ET-A antagonist
- endothelin receptor antagonist
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Cross-references
Synonyms
- Ro670565
- RO-67-0565
- SPP-301
- SPP301
- SPP 301
- Ro 67-0565
- N-[6-methoxy-5-(2-methoxyphenoxy)-2-pyridin-4-yl-pyrimidin-4-yl]-5-methyl-pyridine-2-sulfonamide
- 5-methylpyridine-2-sulfonic acid (6-methoxy-5-(2-methoxyphenoxy)-2-(pyridin-4-yl)pyrimidin-4-yl)amide
- L94KSX715K
- avosentanum
- RefChem:115805
- DTXCID40105821
- Avosentan [INN]
- UNII-L94KSX715K
- MFCD23843806
- Avosentan [WHO-DD]
- GTPL8260
- orb1296080
- SCHEMBL2742679
- SCHEMBL29379732
- C23H21N5O5S
- YBWLTKFZAOSWSM-UHFFFAOYSA-N
- HMS3741G07
- QLA81526
- Avosentan,CAS:290815-26-8
- BDBM50532577
- TQ0282
- CS-0625
- NCGC00379058-01
- AC-33590
- DA-71170
- HY-15195
- MS-28915
- Ro 67-0565; SPP-301
- F84811
- L001646
- BRD-K19203487-001-01-4
Look up AVOSENTAN in the interactive SynDRA portal →